Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy

Sponsor
Beijing Ditan Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05929963
Collaborator
(none)
300
1
19.8
15.1

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about he effects of hepatitis C virus on pregnancy. The main question[s] it aims to answer are:

Effect of hepatitis C virus on liver function in pregnant women Mother-to-child transmission rate in pregnant women with hepatitis C

Condition or Disease Intervention/Treatment Phase
  • Other: HCV infection status

Detailed Description

This study aims to collect demographic data, biochemical indicators during pregnancy, pregnancy complications, and fetal outcomes through the hospital HIS and LIS systems to investigate the impact of HCV infection on pregnancy outcomes, mother-to-child transmission, and long-term child development, and to provide assistance in the clinical management of pregnant women with HCV infection.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy
Actual Study Start Date :
May 9, 2023
Anticipated Primary Completion Date :
Feb 20, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
HCV Ab(+)HCVRNA(-)

HCV Ab(+) HCVRNA(-) in pregnant women

Other: HCV infection status
Divided into 3 groups based on HCVAb and HCVRNA status

HCV Ab(+)HCVRNA(+)

HCV Ab(+)HCVRNA(+)in pregnant women

Other: HCV infection status
Divided into 3 groups based on HCVAb and HCVRNA status

HCVAb(-) HCVRNA(-)

HCV Ab(-)HCVRNA(-)in pregnant women

Other: HCV infection status
Divided into 3 groups based on HCVAb and HCVRNA status

Outcome Measures

Primary Outcome Measures

  1. Incidence of various adverse pregnancy outcomes [2023-2025]

    The probability of postpartum haemorrhage, gestational diabetes mellitus and gestational hypertension in pregnant women infected with hepatitis C virus and the associated factors affecting them

Secondary Outcome Measures

  1. Mother-to-child transmission rate of HCV [2023-2025]

    Mother-to-child transmission rate of HCV in pregnant women and correlation with HCV RNA viral load

  2. Development of children born to HCV pregnant women [2023-2025]

    We will follow up on the child's weight (weight in kilograms), heigh(height in meters),Body mass index(BMI described in kg/m^2) ,head circumference(Head circumference described in metres),Head up, roll over, sit, crawl, stand and talk start time(Describe time in months).

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • normal (anti-HCV negative) or RNA negative (anti-HCV positive and HCV RNA negative) or RNA positive (anti-HCV positive and HCV RNA positive) pregnant women

  • pregnant women aged 20-45 years

  • complete pregnancy data available

Exclusion Criteria:
  • Combination of other liver diseases such as viral hepatitis (hepatitis A, B, D, E), alcoholic hepatitis, autoimmune hepatitis, metabolic hepatitis, non-alcoholic fatty liver disease

  • Combination of other viral infections with potential loss of liver function

  • Mental illness

  • Patients with immunosuppression

  • Mother with cirrhosis or liver tumour

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Ditan Hospital Beijing China

Sponsors and Collaborators

  • Beijing Ditan Hospital

Investigators

  • Principal Investigator: Yao Xie, Doctor, Beijing Ditan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yao Xie, Head of Department, Beijing Ditan Hospital
ClinicalTrials.gov Identifier:
NCT05929963
Other Study ID Numbers:
  • DTXY28
First Posted:
Jul 5, 2023
Last Update Posted:
Jul 5, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2023